MedTrace Logo

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

NCT01766778 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider initiating Vildagliptin and taking balance between efficacy, compliance, risk factors, convenience and medication cost.

Conditions

  • Type-2 Diabetes Mellitus

Interventions

DRUG

LAF237 (vildagliptin)

Vildagliptin 50mg capsule

DRUG

Metformin

Metformin maximum tolerance dose

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-13
Primary Completion
2015-10-22
Completion
2015-10-22

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01766778 on ClinicalTrials.gov